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RADIOTHERAPY AND TEMOZOLOMIDE IN GLIOBLASTOMA:
PREDICTIVE FACTORS OF RESPONSE TO THE TREATMENT
M. Santoro. Operative Unity of Radiotherapy and Radiobiology
Hospital Pugliese-Ciaccio, Via Pio X, 88100 Catanzaro, Italy
Despite the efforts to improve the standard treatment [sur-
gery, radiotherapy (RT) and chemotherapy], at present, the med-
ian survival of patients with glioblastoma (GBM) is poor and
almost of patients die for local recurrence. In 2005, the trial of
EORTC/NCIC1 have established what the treatment with concom-
itant temozolamide (TMZ) and RT (plus adjuvant TMZ) has
increased the overall survival since 10% (after the RTalone) to
the 26% (after combined treatment). This benefit however is not
reached in all the patients, because of the presence of molecular
abnormality among the patients and also inside the same patient.
The aetiology of GBM is unknown, and’ is brought that at least
two genetic pathways is implicated in its development: primary
(de novo) and secondary glioblastoma. Temozolamide is a new
alkylant agent, orally active, derived from dacarbazine with pro-
ven efficacy in the treatment of GBM. Hegi et al.2 have reported
what the mechanism of action of the TMZ resides in the alkyl-
ation of the DNA (position O6 of the guanine): such damage
comes in the normally by the O6-methyl guanine-DNA methyl
transferase (MGMT) (Fig. 1).
The MGMT is implicated in the tumoural resistance since it is
partially able invalidate the effect of the alkylant agents on the O6
guanine. The study of Hegi et al.3 has brought that the patients,
treated with TMZ+RT in which the promoting gene of the MGMT
is methylated they show a median survival (at 2 years) of 46%, in
comparison to those essays with RT alone, for which instead the
survival is of 23%. In the patients that introduce the promoter
gene unmethylated they show a survival, at 2 years, after treat-
ment with TMZ + RT, of 14%. Chakravarti et al.4 in the 2006, using
a panel of four primary human glioblastoma cells, reported that
TMZ ‘enhances radiation response most effectively in MGMT-negative
glioblastomas by increasing the degree of radiation-induced double-
strand DNA damage. In MGMT-positive glioblastomas, depletion of
MGMT by the addition of the O(6)-benzylguanine significantly enhances
the antitumour effect of concurrent radiation+ temozolamide.’
Additionally, Sarkaria et al.5 studying a panel of GBM ortho-
topic xenograft, have reported that the treatment with TMZ did
not sensitize tumours presenting MGMT unmethylated to radia-
tion, but the treatment with TMZ appears to sensitize MGMT-
methylated tumours to radiation.
Moreover, the temozolamide expounds also its function alky-
lant in the respects of the position N-7 of the guanine and the
Fig. 1. Image reported from Metha MP, X Congresso Nazionale e Corso Residenziale dell’Associazione Italiana di Neuro-
Oncologia, Napoli 7–9 Novembre 2005.
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position N-3 of the adenine, whose damages are mended then by
enzymes of the family of the PARP. The latter two are repaired by
enzymes in the base excision pathway, which can be inhibited by
PARP inhibitors (Fig. 2).
At present, are ongoing clinical trials using MGMT or PARP
inhibitors to overcome the TMZ resistance.6
The TMZ, in preclinical data, shows an additive effect with the
radiation.7
In conclusion, in the treatment of glioblastoma, further stud-
ies are need to the purpose to integrate basic research and clinical
practice.
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CONTRIBUTION OF THE FUNCTIONAL IMAGING IN THE RADIO-
THERAPY TREATMENT PLANNING FOR MALIGNANT GLIOMA:
REVISION OF THE LITERATURE
M. Santoro, P. Petitto, D. Pingitore. Operative Unity of Radiotherapy
and Radiobiology, Hospital Pugliese-Ciaccio, Catanzaro, Italy
Currently, despite the efforts to improve the standard treat-
ment [surgery, radiotherapy (RT) and chemotherapy], the median
survival of patients with glioblastoma (GBM) is poor and almost of
patients die for local recurrence, both to the inside and to the out-
side of the tumoural bed. In consideration of the disappointing
gotten results, the question that emerges if it is possible to
improve radiotherapy planning integrating of new imaging tech-
niques. To the moment the standard is the use of the imaging
CT and Magnetic Resonance Imaging (MRI)-based, but for
instance MRI is not able to differentiate residual tumour and
post-operating modifications. In addition to the anatomic and
morphological findings available with con conventional imaging
methods, advanced MRI and Nuclear Medicine (NM) techniques
can give information on the metabolism of malignant glioma
cells. In this study we have analysed the following methodic of
functional imaging: 123I-alpha-methil-tyrosine-single photon
emission CT (IMT-SPECT), single-voxel proton magnetic reso-
nance spectroscopy (1H-MRS), functional MRI, diffusion tensor
imaging (DFI), [F-18]-fluorodeoxyglucose positron tomography
(18FDG-PET) and L-(methyl-11C)-labelled methionine positron
emissions tomography (MET-PET), to the purpose to integrate
her in the target delineation and in radiation dose escalation.
Every of the new techniques show potentiality and limits. For
instance, in comparison with 1H-MRS, 123I-IMT-SPECT introduces
best results in to distinguish amongst recurrent and/or residual
tumour from the post-operative changes and can be useful in
the definition of the volume target with greater accuracy and in
consideration of ‘the high specificity of the IMT uptake for the tumour
tissue, the findings on IMT-SPECT may significantly modify the target
volumes for radiotherapy planning. This will help to focus the high irra-
diation dose on the tumour area and to spare normal brain tissue’.1 The
1H-MRSI showing a high specificity and sensibility in to distin-
guish between therapy-related effects and relapse, it finds her
application in the assessment of probability of response or failure
to the treatment. Since, radiation dose escalation in malignant
glioma may lead to an increase of the disease control, the
18FDG-PET may be of great utility in to define the regions for
which to plan to radiation dose boost. The assessment of diffu-
sion properties may add information, during the follow-up, in to
distinguish between recurrence and radiation effects. In post-
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Fig. 2. Image reported from Metha MP, X Congresso Nazionale e Corso Residenziale dell’Associazione Italiana di Neuro-
Oncologia, Napoli 7–9 Novembre 2005.
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